• Clinical and Experimental Pediatrics
• /
• v.62 no.8
• /
• pp.287-291
• /
• 2019

Fecal calprotectin (FC) is a calcium- and zinc-binding protein of the S100 family, mainly expressed by neutrophils and released during inflammation. FC became an increasingly useful tool both for gastroenterologists and for general practitioners for distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome. Increasing evidences support the use of this biomarker for diagnosis, follow-up and evaluation of response to therapy of several pediatric gastrointestinal diseases, ranging from IBD to nonspecific colitis and necrotizing enterocolitis. This article summarizes the current literature on the use of FC in clinical practice.

• Korean Journal of Psychosomatic Medicine
• /
• v.13 no.1
• /
• pp.3-15
• /
• 2005

Objectives The author aimed to investigate and understand the limitations of the biopsychosocial model for irritable bowel syndrome by reviewing the priorly reported etiologies in patients with irritable bowel syndrome(IBS). Methods The author reviewed all possible previous studies related to the investigation regarding IBS in the Pub-med & Kisep database from 1977 to 2003. Results : It was impossible that patients with IBS were diagnosed and traced to a single etiology. So, the biopsychosocial model was suggested to be a new paradigm for IBS. Biological, psychological and social factors are interplaying and contributing to the biopsychosocial model affecting each other, thus affecting the biopsychosocial model. Three factors were necessary for understanding the etiology, process of symptoms and clinical outcome of IBS by virtue of their key roles in the developing, precipitating and perpetuating of the illness. However, any treatment application for those three factors faces many obstacles to be overcome. Conclusion : The biopsychosocial model contributed relatively much to the explanation but little to the treatment application of patients with IBS. Therefore, because there seems to be little practical use at present, the author believes biopsychosocial aspects should be researched further.

• Journal of Digital Convergence
• /
• v.16 no.11
• /
• pp.501-509
• /
• 2018

The purpose of this study is to explore the effects of acceptance and commitment Therapy(ACT) on IBS-symptoms, stress, quality of life, and acceptance-action of people with irritable bowel syndrome(IBS). After 156 adults completed Rome III Adult Questionnaire, Fourteen participants selected to 7 in ACT group and 7 in the control group. All participants completed IBS Severity Scale, K-IBS-QOL, Acceptance & Action Questionnaire-16 at the pre-test, post-test, and the 4 weeks follow-up. The ACT programme was administered for 10 sessions. Dedicated people who participated in the study were 6 in ACT group, and 6 in the control group. As a result, ACT has positive effects on the change of perceived stress, quality of life, and acceptance-action, while has not on IBS-symptoms. This study suggest empirical evidence to prove that the ACT is effective in reducing stress and improving quality of life, and acceptance-action of IBS peoples. However, The study has only few participants and thus has limitations.

• Korean Journal of Psychosomatic Medicine
• /
• v.11 no.1
• /
• pp.69-76
• /
• 2003

Objectives: Many researches have been done to compare psychopathology of functional gastrointestinal disorder and inflammatory bowel disease which involves structural change. Recently, many studies focused on the topic of alexithymia. The results from these studies were questionable for lack of valid measures of alexithymia and valid diagnostic criteria of functional gastrointestinal disorders. Therefore, we tried to overcome these two problems and to assess alexithymia, personality characteristics, and other psychopathology. Methods: The subjects consisted of ulcerative colitis group(N=28) who were diagnosed by colonoscopy and biopsy, irritable bowel syndrome group(N=27) who were diagnosed by Rome II criteria and normal control group(N=22). All patients were diagnosed at outpatient department of Kyungpook National University Hospital. All these groups completed three psychological tests, including MMPI, Rorschach test, and well validated TAS-20K(The Korean Version of the 20-Item Toronto Alexithymia Scale). Results: Twenty-five percent of the ulcerative colitis group and 22% of the irritable bowel syndrome group scored in the alexithymia range, compared with 0% of the normal group. In Rorschach test, irritable bowel syndrome group showed high levels of weighted Sum C and EA. Most of clinical scales of MMPI were higher in two gastrointestinal groups than the normal control group. And two gastrointestinal groups showed low ego strength level, but there was no statistical significant difference between them. Conclusion: Two gastrointestinal groups showed high rate of alexithymia, other psychopathological profiles, and low ego strength but there was no significant difference between two groups.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.12 no.2
• /
• pp.120-132
• /
• 2009

Purpose: We diagnosed pediatric functional gastrointestinal disorders in Korean children and adolescents using Rome III criteria and investigated the clinical validity of QPGS-Rome III. Methods: Diagnosis based on QPGS was compared with the physician's diagnosis based on Rome III criteria. One hundred and thirty eight children and their parents completed the QPGS. Agreement rates were measured using Kappa method. Results: In physician's diagnoses, the most prevalent disorders were functional dyspepsia (39.1%), irritable bowel syndrome (38.4%), and functional abdominal pain (18.8%). Among QPGS based diagnoses, the most prevalent disorders were irritable bowel syndrome (39.1%), functional dyspepsia (29.7%), and functional abdominal pain (21.7%). The agreement rate was substantial (${\kappa}$=0.72, p=0.00). Diagnostic disagreements probably resulted from different patient responses to bowel movement form and bowel frequency. Conclusion: Functional dyspepsia, irritable bowel syndrome, and functional abdominal pain were the most common disorders by Rome III criteria in the Korean pediatric and adolescent patients. The agreement rate between physician's diagnoses and QPGS based diagnoses supported the validity of the QPGS-Rome III in Korean pediatric and adolescent patients. QPGS seems to be useful in diagnosis of patients with functional gastrointestinal disorders by Rome III criteria.

• BMB Reports
• /
• v.51 no.9
• /
• pp.429-436
• /
• 2018

Fructose in the form of sucrose and high fructose corn syrup is absorbed by the intestinal transporter and mainly metabolized in the small intestine. However, excess intake of fructose overwhelms the absorptive capacity of the small intestine, leading to fructose malabsorption. Carbohydrate response element-binding protein (ChREBP) is a basic helix-loop-helix leucine zipper transcription factor that plays a key role in glycolytic and lipogenic gene expression in response to carbohydrate consumption. While ChREBP was initially identified as a glucose-responsive factor in the liver, recent evidence suggests that ChREBP is essential for fructose-induced lipogenesis and gluconeogenesis in the small intestine as well as in the liver. We recently identified that the loss of ChREBP leads to fructose intolerance via insufficient induction of genes involved in fructose transport and metabolism in the intestine. As fructose consumption is increasing and closely associated with metabolic and gastrointestinal diseases, a comprehensive understanding of cellular fructose sensing and metabolism via ChREBP may uncover new therapeutic opportunities. In this mini review, we briefly summarize recent progress in intestinal fructose metabolism, regulation and function of ChREBP by fructose, and delineate the potential mechanisms by which excessive fructose consumption may lead to irritable bowel syndrome.

• Journal of Ginseng Research
• /
• v.29 no.2
• /
• pp.94-99
• /
• 2005

In the previous study, we reported that the in viかo inhibitory effect of ginsenosides, active ingredient of Panax ginseng, on $5-HT_{3A}$ receptor channel activity is coupled to in vivo anti-vomiting and anti-nausea effect. In the present study, we further investigated that the inhibitory effect of ginsenosides, active ingredient of Panax ginseng, on 5-HT3A receptor channel activity is also coupled to attenuation of irritable bowel syndrome (IBS), which is induced by colorectal distention (CRD) and $0.6\%$ acetic acid treatment. The CRD-induced visceral pains induced by CRD and acetic acid treatment are measured by frequency of contractions of the external oblique muscle in conscious rats. Treatment of GTS significantly inhibited CRD-induced visceral pain with dose-dependent manner. The $EC_{50}$ was $5.5{\pm}4.7$ mg/kg ($95\%$ confidence intervals: 1.2-15.7) and the antinociceptive effect of GTS on visceral pain was persistent for 4 h. We also compared the effects of protopanaxadiol (PD) ginsenosides and protopanaxatriol (PT) ginsenosides with saline on acetic acid-and CRD-induced visceral pain, and found that protopanaxatriol (PT) ginsenosides was much more potent than PD ginsenosides in attenuating CRD-induced visceral pain. These results indicate that U ginsenosides of Panax ginseng are components far attenuation of experimentally CRD-induced visceral pains.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.21 no.4
• /
• pp.264-270
• /
• 2018

Purpose: The aim of this study was to describe functional gastrointestinal disorders (FGID) presented in a tertiary medical center, characteristics of patients and results of the diagnostic work-up together with an outcome during the follow up. Methods: This was a retrospective, single center, observational study including all patients who were diagnosed with FGID based on Rome III criteria from January to December 2015 in tertiary medical center. Results: Overall 294 children were included (mean age, 8.9 years [range, 1-18 years]; 165 females). Majority had functional constipation (35.4%), followed by functional abdominal pain (30.6%), irritable bowel syndrome (17.0%), functional dyspepsia (12.6%), functional nausea (3.4%) and abdominal migraine (1.0%). Regression model found that only significant factor associated with improvement of symptoms is the establishment of the functional diagnosis at the first visit (hazard ratio, 2.163; 95% confidence inverval, 1.029-4.544). There was no association between improvement of symptoms and presence of alarm signs/symptoms (weight loss, nocturnal symptoms and severe vomiting) at diagnosis. Furthermore, in pain symptoms (functional abdominal pain, irritable bowel syndrome, dyspepsia) no treatment positively correlated with pain improvement. Conclusion: Regardless of the initial diagnosis of FGID, positive diagnosis at the first visit increases a chance for resolution of symptoms.

• Korean Journal of Occupational Health Nursing
• /
• v.18 no.2
• /
• pp.281-288
• /
• 2009

Purpose: This study was to investigate the relationship between IBS and nurses' occupational stress. Method: We used the modified Rome III criteria to measure the relationship between IBS and nurses' occupational stress. This questionnaire is composed of 9 areas and 43 items related to the stress. We collected the data of 395 respondents from W hospital. The survey was done from July 10th to July 31th, 2009. Results: The morbidity of IBS showed 24.3%. It was significantly influenced by night shift, and hospital visits and medication because of abdominal discomfort for the past 6 months. The causes of the nurses' occupational stress, which influenced the difference between IBS and non-IBS group, were "conflict with doctors" "difficulties in human relationships" "dealing with guardians and patients". The IBS group's stress was higher that of the non-IBS group. Also 96.9% of the IBS group and 79.3% of the non-IBS group responded there was relationship between IBS and nurses occupational stress. Conclusion: We found the relationship between IBS and nurses' occupational stress. And such stress could be reduced through the education about IBS.

• Biomolecules & Therapeutics
• /
• v.29 no.4
• /
• pp.353-364
• /
• 2021

The gastrointestinal (GI) tract is a series of hollow organs that is responsible for the digestion and absorption of ingested foods and the excretion of waste. Any changes in the GI tract can lead to GI disorders. GI disorders are highly prevalent in the population and account for substantial morbidity, mortality, and healthcare utilization. GI disorders can be functional, or organic with structural changes. Functional GI disorders include functional dyspepsia and irritable bowel syndrome. Organic GI disorders include inflammation of the GI tract due to chronic infection, drugs, trauma, and other causes. Recent studies have highlighted a new explanatory mechanism for GI disorders. It has been suggested that autophagy, an intracellular homeostatic mechanism, also plays an important role in the pathogenesis of GI disorders. Autophagy has three primary forms: macroautophagy, microautophagy, and chaperone-mediated autophagy. It may affect intestinal homeostasis, host defense against intestinal pathogens, regulation of the gut microbiota, and innate and adaptive immunity. Drugs targeting autophagy could, therefore, have therapeutic potential for treating GI disorders. In this review, we provide an overview of current understanding regarding the evidence for autophagy in GI diseases and updates on potential treatments, including drugs and complementary and alternative medicines.